

Thrombosis & Platelets

Bibliography of One Hundred Key Papers

selected by **Pierre Theroux, MD**

Department of Medicine - Montreal Heart Institute - University of Montreal
5000 Belanger East - Montreal - Quebec - CANADA (e-mail: theroux@ICM.Umontreal.ca)

Dialogues Cardiovasc Med. 2002;7:60-68

-
- Antiplatelet Trialists' Collaboration.** Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
BMJ. 1994;308:81-106.
-
- Antman EM, Cohen M, Radley D, et al.** Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. *TIMI 11B-ESSENCE meta-analysis.*
Circulation. 1999;100:1602-1608.
-
- Antman EM, for the TIMI 9B Investigators.** Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial.
Circulation. 1996;94:911-921.
-
- Antman EM, Giugliano RP, Gibson CM, et al, for the TIMI-14 Investigators.** Abciximab facilitates the rate and extent of thrombolysis: results of Thrombolysis in Myocardial Infarction (TIMI) 14 trial.
Circulation. 1999;99:2720-2732.
-
- Antman EM, McCabe CH, Gurfinkel EP, et al.** Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Circulation. 1999;100:1593-1601.
-
- Aukrust P, Muller F, Ueland T, et al.** Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.
Circulation. 1999;100:614-620.
-
- Badimon JJ, Lettino M, Toschi V, et al.** Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions.
Circulation. 1999;99:1780-1787.
-
- Balsano F, Rizzon P, Violi F, et al.** Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group.
Circulation. 1990;82:17-26.
-
- Becker RC, Ball SP, Eisenberg P, et al.** A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease: Antithrombotic Therapy Consortium Investigators.
Am Heart J. 1999;137:59-71.
-



-
- Bertrand ME, Simoons ML, Fox KA, et al.** *Management of acute coronary syndromes: acute coronary syndromes without persistent ST-segment elevation. Recommendations of the Task Force of the European Society of Cardiology.* **Eur Heart J.** 2000;21:1406-1432.
-
- Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ.** *Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.* **Circulation.** 2001;103:363-368.
-
- Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML.** *Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes.* **Circulation.** 1999;100:2045-2048.
-
- Braunwald E, Antman EM, Beasley JW, et al.** *ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina).* **Circulation.** 2000;102:1193-1209.
-
- Braunwald E, Mark DB, Jones RH, et al.** *Unstable angina: diagnosis and management. Rockville, MD: Agency for Health Care Policy Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Thrombolysis In Myocardial Ischemia.* **Circulation.** 1994;89:1545-1556.
-
- Cairns JA, Gent M, Singer J, et al.** *Aspirin, sulfipyrazone, or both in unstable angina. Results of a Canadian multicenter trial.* **N Engl J Med.** 1985;313:1369-1375.
-
- Cannon CP, McCabe CH, Wilcox RG, et al.** *Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.* **Circulation.** 2000;102:149-156.
-
- Cannon CP, Weintraub WS, Demopoulos LA, et al.** *Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.* **N Engl J Med.** 2001;344:1879-1887.
-
- Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA.** *The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo e-deficient mice. Evidence that eicosanoids other than thromboxane contribute to atherosclerosis.* **Arterioscler Thromb Vasc Biol.** 2000;20:1724-1728.
-
- Chew DP, Bhatt DL, Sapp S, Topol EJ.** *Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.* **Circulation.** 2001;103:201-206.
-
- Cipollone F, Ciabattini G, Patrignani P, et al.** *Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina.* **Circulation.** 2000;102:1007-1013.
-
- Cohen M.** *Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST-segment elevation acute coronary syndromes.* **J Invasive Cardiol.** 2000;12(suppl E):E5-E9; discussion E25-E28.
-

Bibliography of One Hundred Key Papers

- Cohen M, Adams PC, Parry G, et al.** *Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.*
Circulation. 1994;89:81-88.
-
- Cohen M, Demers C, Gurfinkel EP, et al.** *A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.*
N Engl J Med. 1997;337:447-452.
-
- Coller BS.** *Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy.*
Circulation. 1995;92:2373-2380.
-
- Coller BS.** *Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions.*
Thromb Haemost. 1999;82:326-336.
-
- Colombo A, Hall P, Nakamura S, et al.** *Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.*
Circulation. 1995;91:1676-1688.
-
- Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP.** *Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets.*
J Biol Chem. 1998;273:2024-2029.
-
- Davies MJ, Richardson PD, Woolf N, et al.** *Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.*
Br Heart J. 1993;69:377-381.
-
- de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N.** *Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.*
Circulation. 1999;99:779-785.
-
- Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A.** *European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.*
J Neurol Sci. 1996;143:1-13.
-
- Doucet S, Malekianpour M, Theroux P, et al.** *Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty.*
Circulation. 2000;101:955-961.
-
- Eikelboom JW, Anand SS, Malmberg K, et al.** *Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.*
Lancet. 2000;355:1936-1942.
-
- FRISC Study Group.** *Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.*
Lancet. 1996;347:561-568.
-
- FRISC II Investigators.** *Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study.*
Lancet. 1999;354:708-815.
-



-
- Fuster V, Badimon L, Badimon JJ, Chesebro JH.** *The pathogenesis of coronary artery disease and the acute coronary syndromes.*
N Engl J Med. 1992;326:242-250.
-
- Granger CB, Hirsch J, Califf RM, et al.** *Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.*
Circulation. 1996;93:870-878.
-
- Gurfinkel EP, Manos EJ, Mejail RI, et al.** *Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.*
J Am Coll Cardiol. 1995;26:313-318.
-
- Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T.** *Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I.*
N Engl J Med. 1997;337:1648-1653.
-
- Hamm CW, Heeschen C, Goldmann B, et al.** *The CAPTURE Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels.*
N Engl J Med. 1999; 340:1623-1629.
-
- Hamm CW, Ravkilde J, Gerhardt W, et al.** *The prognostic value of serum troponin T in unstable angina.*
N Engl J Med. 1992;327:146-150.
-
- Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA.** *Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.*
Arch Neurol. 2000;57:326-332.
-
- Hebert PR, Hennekens CH.** *An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.*
Arch Intern Med. 2000;160:3123-3127.
-
- Heeschen C, Hamm CW, Bruemmer J, Simoons ML.** *Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis.*
J Am Coll Cardiol. 2000;35:1535-1542.
-
- Herbert JM, Savi P, Maffrand JP.** *Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist.*
Eur Heart J. 1999;21:A31-A40.
-
- Ingall AH, Dixon J, Bailey A, et al.** *Antagonists of the platelet P2T receptor: a novel approach to anti-thrombotic therapy.*
J Med Chem. 1999;42:213-220.
-
- ISIS-2 Collaborative Group.** *Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.*
Lancet. 1988;2:349-360.
-
- Jarvis GE, Humphries RG, Robertson MJ, Leff P.** *ADP can induce aggregation of human platelets via both P2Y(1) and P(2T) receptors.*
Br J Pharmacol. 2000;129:275-282.
-

Bibliography of One Hundred Key Papers

- Klein W, Buchwald A, Hillis SE, et al.** *Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).*
Circulation. 1997;96:61-68.
-
- Lee Y, Lee WH, Lee SC, et al.** *CD40L activation in circulating platelets in patients with acute coronary syndrome.*
Cardiology. 1999;92:11-16.
-
- Leon MB, Baim DS, Popma JJ, et al.** *A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.*
N Engl J Med. 1998;339:1665-1671.
-
- Lewis HD Jr, Davis JW, Archibald DG, et al.** *Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.*
N Engl J Med. 1983;309:396-403.
-
- Libby P.** *Current concepts of the pathogenesis of the acute coronary syndromes.*
Circulation. 2001;104:365-372.
-
- Libby P, Simon DI.** *Inflammation and thrombosis: the clot thickens.*
Circulation. 2001;103:1718-1720.
-
- Lindahl B, Venge P, Wallentin L.** *Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.*
J Am Coll Cardiol. 1997;29:43-48.
-
- Liuzzo G, Biasucci LM, Gallimore JR, et al.** *The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.*
N Engl J Med. 1994;331:417-424.
-
- Mach F, Schonbeck U, Libby P.** *CD40 signaling in vascular cells: a key role in atherosclerosis?*
Atherosclerosis. 1998;137(suppl):S89-S95.
-
- Mark DB, Cowper PA, Berkowitz SD, et al.** *Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (unstable angina or non-Q-wave myocardial infarction).*
Circulation. 1998;97:1702-1707.
-
- Markwardt F.** *The development of hirudin as an antithrombotic drug.*
Thromb Res. 1994;74:1-23.
-
- Michelson AD, Furman MI, Goldschmidt-Clermont P, et al.** *Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.*
Circulation. 2000;101:1013-1018.
-
- Montalescot G, Barragan P, Wittenberg O, et al.** *The ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.*
N Engl J Med. 2001;344:1895-1903.
-



-
- Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA.** *A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians.*
Am Heart J. 2001;142:336-339.
-
- Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.** *Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial.*
Lancet. 1999;353:429-438.
-
- O'Shea JC, Hafley GE, Greenberg S, et al.** *Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatid in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.*
JAMA. 2001;285:2468-2473.
-
- Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A.** *Increased neutrophil-platelet adhesion in patients with unstable angina.*
Circulation. 1996;94:1239-1246.
-
- Patrono C, Collier B, Dalen JE, et al.** *Platelet-active drugs: the relationships among dose, effectiveness, and side effects.*
Chest. 2001;119:39S-63S.
-
- Peter K, Schwarz M, Ylance J, et al.** *Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alpha II/beta III) inhibitors.*
Blood. 1998;92:3240-3249.
-
- Petitou M, Duchaussoy P, Jaurand G, et al.** *Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).*
J Med Chem. 1997;40:1600-1607.
-
- Pitt B, Waters D, Brown WV, et al.** *Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.*
N Engl J Med. 1999;341:70-76.
-
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.** *Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.*
N Engl J Med. 1997;336:973-979.
-
- Ridker PM, Hennekens CH, Buring JE, Rifai N.** *C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.*
N Engl J Med. 2000;342:836-843.
-
- Ridker PM, Rifai N, Clearfield M, et al.** *Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.*
N Engl J Med. 2001;344:1959-1965.
-
- Ross AM, Coyne K, Hammond M, Lundergan CF.** *Low-molecular-weight heparins in acute myocardial infarction: rationale and results of a pilot study.*
Clin Cardiol. 2000;23:483-485.
-
- Ross AM, Molhoek P, Lundergan C, et al.** *Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of heparin and aspirin reperfusion therapy (HART II).*
Circulation. 2001;104 648-652.
-

Bibliography of One Hundred Key Papers

- Serruys PW, Herrman JP, Simon R, et al.** *The Helvetica Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty.* **N Engl J Med.** 1995; 333:757-763.
-
- Shah PK, Falk E, Badimon JJ, et al.** *Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture.* **Circulation.** 1995;92:1565-1569.
-
- The Assessment of the Safety and Efficacy of a New New Thrombolytic Regimen (ASSENT)-3 Investigators.** *Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction.* **Lancet.** 2001;358:605-613.
-
- The CAPRIE Steering Committee.** *A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).* **Lancet.** 1996;348:1329-1339.
-
- The CAPTURE Investigators.** *Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study.* **Lancet.** 1997;349:1429-1435.
-
- The EPILOG Investigators.** *Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.* **N Engl J Med.** 1997;336:1689-1696.
-
- The EPISTENT Investigators.** *Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting.* **Lancet.** 1998;352:87-92.
-
- The FRA.X.I.S. Study Group.** *Comparison of two treatment durations (6 days and 14 days) of a low-molecular-weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome).* **Eur Heart J.** 1999;20:1553-1562.
-
- The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators.** *A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.* **N Engl J Med.** 1996;335:775-782.
-
- The GUSTO V Investigators.** *Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.* **Lancet.** 2001;357:1905-1914.
-
- The GUSTO-4 Investigators.** *Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.* **Lancet.** 2001;357:1915-1924.
-
- The PRISM Investigators.** *A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.* **N Engl J Med.** 1998;338:1498-1505.
-



-
- The PRISM-PLUS Investigators.** *Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.*
N Engl J Med. 1998;338:1488-1497.
-
- The PURSUIT Investigators.** *Inhibition of platelet glycoprotein IIb/IIIa with eptifibatid in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Using Integrilin Therapy.*
N Engl J Med. 1998;339:436-443.
-
- The RISC Group.** *Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.*
Lancet. 1990;336:827-830.
-
- Theroux P, Ouimet H, McCans J, et al.** *Aspirin, heparin, or both to treat acute unstable angina.*
N Engl J Med. 1988;319:1105-1111.
-
- Theroux P, Waters D, Lam J, Juneau M, McCans J.** *Reactivation of unstable angina after the discontinuation of heparin.*
N Engl J Med. 1992;327:141-145.
-
- Topol EJ, Byzova TV, Plow EF.** *Platelet GPIIb-IIIa blockers.*
Lancet. 1999;353:227-231.
-
- Topol EJ, Moliterno DJ, Herrmann HC, et al.** *Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.*
N Engl J Med. 2001;344:1888-1894.
-
- Toschi V, Gallo R, Lettino M, et al.** *Tissue factor modulates the thrombogenicity of human atherosclerotic plaques.*
Circulation. 1997;95:594-599.
-
- Turpie AGG, Gallus AS, Hoek JA.** *The Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.*
N Engl J Med. 2001;344:619-625.
-
- The EPIC Investigation.** *Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.*
N Engl J Med. 1994;330:956-961.
-
- Warkentin TE, Levine MN, Hirsh J, et al.** *Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.*
N Engl J Med. 1995;332:1330-1335.
-
- Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM.** *Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications.*
Circulation. 1989;80:198-205.
-
- Xiao Z, Theroux P.** *Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.*
Circulation. 1998;97:251-256.
-

Bibliography of One Hundred Key Papers

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK.

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.
N Engl J Med. 2001;345:494-502.

Zhao XQ, Theroux P, Snapinn SM, Sax FL.

Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms).
Circulation. 1999;100:1609-1615.
